Venetoclax plus Inotuzumab Ozogamicin for Relapsed and Refractory Acute Lymphoblastic Leukemia.

Venetoclax combined with inotuzumab ozogamicin achieves a 95.5% complete remission rate in relapsed/refractory B-cell ALL and LBL patients.

• Why it matters: Relapsed or refractory B-cell ALL and LBL have limited treatment options with short-lived responses, highlighting the need for more effective therapies to improve long-term outcomes.
• What they did: A phase 1 trial enrolled 23 adults with R/R CD22+ ALL/LBL, testing venetoclax at 200-400 mg/day combined with standard-dose inotuzumab ozogamicin, with 21 patients achieving remission.
• The result: The combination was safe, with high rates of MRD negativity and durable remissions, leading to a 48% two-year disease-free survival, supporting further development of this regimen.